human
viral
diseas
method
clone
nativ
human
antibodi
beset
technic
problem
yet
mani
antibodi
specif
viral
antigen
clone
present
review
discuss
nativ
human
antibodi
ongo
improv
clone
method
facilit
creation
novel
potent
antivir
therapeut
obtain
nativ
human
antibodi
repertoir
grow
awar
util
need
human
antibodi
therapeut
viral
diseas
keller
stiehm
oral
et
al
casadeval
et
al
casadeval
pirofski
individu
recov
viral
infect
receiv
therapeut
vaccin
contain
popul
antibodi
capabl
contribut
lifelong
immun
viru
defin
nativ
antibodi
ie
antibodi
exactli
configur
creat
function
intact
human
immun
system
nativ
antibodi
commonli
obtain
method
immort
primari
b
cell
hybridoma
format
epsteinbarr
viru
ebv
infect
distinct
human
human
antibodi
deriv
recombin
dna
transgen
mous
system
may
accur
replic
complet
wildtyp
structur
fulllength
antibodi
produc
human
immun
system
situ
nativ
human
antibodi
repertoir
tremend
potenti
sourc
antivir
antibodi
therapeut
contain
definit
immunolog
solut
human
viral
diseas
like
safest
overal
human
clinic
use
polyclon
antibodi
therapeut
unselect
diseasespecif
nativ
immunoglobulin
effect
clinic
situat
intraven
immunoglobulin
ivig
start
point
explor
potenti
valu
nativ
human
antibodi
immunom
address
vast
spectrum
viral
diseas
antibodi
potenti
therapeut
efficaci
past
year
ongo
effort
improv
method
clone
nativ
human
antibodi
captur
amplifi
antivir
capabl
ivig
progress
demonstr
valu
approach
justifi
explor
review
consid
histori
therapeut
potenti
clone
nativ
human
antibodi
specif
viral
ill
ivig
purifi
popul
nativ
human
igg
antibodi
obtain
blood
plasma
fdaapprov
antivir
use
ivig
treat
infect
parvoviru
pv
patient
immunocompromis
aplast
anemia
tabl
pv
small
dna
viru
normal
children
caus
fifth
diseas
character
fever
malais
typic
bilater
cheek
facial
rash
broliden
et
al
peopl
parvoviru
infect
selflimit
howev
parvoviru
caus
complic
suscept
individu
result
abil
infect
erythroid
progenitor
cell
patient
undergon
allogen
hematopoiet
stem
cell
transplant
sickl
cell
anemia
acut
aplast
crisi
result
parvoviru
infect
broliden
et
al
eid
et
al
fetus
carri
pregnant
women
infect
viru
develop
sever
anemia
complic
infecti
myocard
induc
hydrop
fetali
fetal
loss
ergaz
ornoy
clinic
situat
ivig
often
use
moudgil
et
al
geetha
et
al
broliden
et
al
eid
et
al
human
antibodi
clone
bind
major
minor
capsid
protein
neutral
parvoviru
vitro
arakelov
et
al
gigler
et
al
may
candid
clone
parvoviru
antibodi
therapeut
hepat
picornaviru
contain
positivestrand
rna
genom
caus
acut
selflimit
hepat
fior
et
al
prior
creation
recombin
hepat
vaccin
ivig
routin
given
hepat
prophylaxi
although
fdaapprov
purpos
cdc
fior
et
al
tabl
ivig
still
indic
suspect
nonimmun
contact
peopl
intoler
vaccin
nativ
antibodi
clone
specif
capsid
protein
cerino
et
al
core
antigen
siemoneit
et
al
one
antibodi
clone
capabl
neutral
hepat
vitro
lewi
et
al
potenti
util
ivig
treatment
virus
pv
hepat
broad
reflect
collect
antibodi
immunom
popul
deriv
studi
five
differ
ivig
prepar
reveal
antivir
antibodi
specif
type
herpesvirus
hsv
varicella
zoster
vzv
ebv
measl
mump
rubella
parvoviru
kraus
et
al
differ
ivig
also
note
two
high
level
antibodi
specif
adenoviru
two
high
level
st
loui
enceph
viru
antibodi
panel
eight
ivig
prepar
recent
examin
presenc
vaccinia
viru
vv
neutral
abil
goldsmith
et
al
found
contain
signific
vitro
vivo
vv
neutral
activ
measur
titer
standard
vv
hyperimmun
globulin
vig
even
though
widespread
vv
vaccin
practic
nearli
past
year
ivig
may
also
clinic
activ
west
nile
viru
wnv
wnv
patient
israel
recov
infect
treatment
ivig
notabl
wnv
endem
israel
isra
ivig
high
titer
wnv
antibodi
contrast
ivig
unit
state
found
contain
wnv
antibodi
ivig
also
consid
potenti
benefit
cytomegaloviru
cmv
infect
renal
bone
marrow
transplant
sechet
et
al
soko
et
al
complic
viral
infect
prefer
treat
hyperimmun
globulin
polyval
ivig
obtain
subject
hightit
antibodi
respons
specif
antigen
tabl
virus
treat
categori
therapeut
hepat
b
hbv
cmv
vzv
vv
rabi
respiratori
syncyti
viru
rsv
first
three
virus
share
capabl
reactiv
patient
becom
immunocompromis
set
hyperimmun
globulin
use
amelior
immunodefici
bring
reactiv
virus
control
vv
caus
acut
infect
sever
manifest
immunocompromis
host
mitig
vvspecif
hyperimmun
globulin
rabi
induc
acut
infect
invari
fatal
unless
treat
even
immunocompet
individu
rabi
immun
globulin
rig
provid
initi
control
viru
concomitantli
administ
vaccin
induc
perman
immun
rsv
caus
fatal
bronchiol
prematur
infant
recipi
allogen
hematopoiet
stem
cell
transplant
patient
popul
rsv
immunoglobulin
rsvig
effect
rsv
prophylaxi
treatment
differ
role
hyperimmun
globulin
empir
defin
reflect
uniqu
clinic
featur
viru
infect
host
virus
nativ
human
antibodi
clone
may
possess
function
provid
hyperimmun
globulin
futur
optim
hyperimmun
globulin
would
consist
similar
antibodi
complet
defin
monoclon
oligoclon
antivir
therapi
hbv
partial
doublestrand
dna
viru
transmit
direct
contact
infect
bodili
fluid
holling
liang
normal
individu
hepat
b
gener
induc
selflimit
hepat
capac
establish
chronic
activ
state
eventu
lead
cirrhosi
hepatocellular
carcinoma
unit
state
hepat
b
immun
globulin
hbig
prepar
small
number
donor
hyperimmun
hbsag
vaccin
terrault
vya
main
three
categori
use
hbig
postexposur
prophylaxi
nonimmun
contact
inhibit
vertic
transmiss
viru
birth
prevent
relaps
hbvposit
patient
follow
orthotop
liver
transplant
follow
suspect
infect
needlestick
fluid
exposur
hbig
recommend
administ
combin
hbsag
vaccin
cdc
maternalfet
transmiss
inhibit
administr
hbig
hbsag
vaccin
immedi
birth
infant
mother
posit
circul
hbe
antigen
hbv
dna
lo
et
al
ip
et
al
kabir
et
al
improv
outcom
may
also
achiev
passiv
immun
hbeposit
mother
hbig
prior
deliveri
xu
et
al
xiao
et
al
success
use
orthotop
liver
transplant
treat
endstag
liver
diseas
caus
hbv
depend
prevent
reactiv
viru
immunocompromis
posttranspl
patient
gish
mccashland
hbig
collabor
nucleosid
antivir
agent
limit
reactiv
patient
remain
risk
reactiv
diseas
discontinu
prophylact
therapi
set
cost
longterm
hbig
administr
may
potenti
reduc
use
lowdos
combin
therapi
regimen
di
paolo
et
al
ferretti
et
al
mani
nativ
human
igg
antibodi
specif
hbv
clone
use
hybridoma
ebvimmort
method
stricker
et
al
colucci
et
al
desgrang
et
al
ichimori
et
al
tiebout
et
al
andri
et
al
ehrlich
et
al
saadu
et
al
heijtink
et
al
anim
data
difficult
obtain
hbv
infect
combin
two
human
antibodi
administ
chimpanze
chronic
infect
hbv
abl
transient
day
reduc
level
circul
viru
heijtink
et
al
import
concern
regard
efficaci
clone
antibodi
hbv
appar
abil
viru
escap
neutral
polyclon
hbig
phenomenon
observ
liver
transplant
patient
recurr
hbv
infect
liver
transplant
despit
hbig
therapi
three
studi
exist
mutat
antigen
region
hbsag
correl
resist
recurr
hbv
infect
carman
et
al
ghani
et
al
terrault
et
al
furthermor
length
time
therapi
correl
likelihood
find
mutat
hbv
strain
ghani
et
al
terrault
et
al
potenti
failur
polyclon
antibodi
may
suggest
viru
would
particularli
adept
escap
effect
monoclon
oligoclon
antibodi
therapeut
pair
antibodi
signific
hbv
bind
consider
less
affin
variant
hbv
strain
arisen
patient
follow
year
hbig
therapi
heijtink
et
al
nonetheless
may
possibl
creat
oligoclon
hbig
equival
superior
polyclon
hbig
identifi
two
three
noncrossresist
antibodi
direct
rel
stabl
portion
hbsag
cmv
doublestrand
dna
viru
normal
individu
induc
febril
ill
resembl
mononucleosi
ebv
chill
fatigu
headach
malais
gandhi
khanna
immunocompromis
patient
undergon
bone
marrow
organ
transplant
advanc
human
immunodefici
viru
hiv
diseas
cmv
caus
consider
morbid
mortal
cmv
may
reactiv
previous
infect
person
becom
immunosuppress
altern
de
novo
cmv
infect
may
transmit
cmvneg
recipi
organ
cmvposit
donor
mani
organ
affect
cmv
infect
includ
retina
lung
liver
esophagu
colon
cmv
also
caus
complic
fetu
infect
utero
includ
hear
loss
visual
loss
neurolog
complic
fowler
et
al
cmv
hyperimmun
globulin
cmvig
first
demonstr
efficaci
treatment
diseas
associ
kidney
transplant
snydman
et
al
sinc
cmvig
approv
fda
treatment
cmv
reactiv
patient
transplant
kidney
heart
lung
liver
pancrea
sawyer
evid
clearli
support
use
ivig
cmvig
allogen
bone
marrow
transplant
patient
ziko
et
al
soko
et
al
util
cmvig
organ
transplant
set
lessen
avail
potent
small
molecul
anticmv
drug
ganciclovir
valganciclovir
foscarnet
cidofovir
even
though
drug
signific
toxic
biron
possibl
cmvig
may
synerg
small
molecul
anticmv
drug
clinic
situat
kocher
et
al
varga
et
al
ruttmann
et
al
mani
nativ
human
monoclon
antibodi
specif
cmv
describ
emanuel
et
al
redmond
et
al
foung
et
al
bron
et
al
kitamura
et
al
drobyski
et
al
gustafsson
et
al
ohizumi
et
al
ohlin
et
al
rioux
et
al
found
capabl
neutral
cmv
vitro
redmond
et
al
foung
et
al
ohizumi
et
al
ohlin
et
al
nativ
human
cmv
antibodi
test
clinic
efficaci
drobyski
et
al
random
control
trial
allogen
hematopoiet
stem
cell
transplant
patient
benefit
antibodi
seen
term
time
develop
cmv
viremia
antigenemia
boeckh
et
al
studi
antibodi
aid
patient
newli
diagnos
recurr
cmv
retin
show
reduct
progress
cmv
diseas
cdc
borucki
et
al
explan
disappoint
result
unclear
antibodi
specif
h
glycoprotein
possibl
antibodi
specif
b
glycoprotein
complex
major
target
cmv
neutral
antibodi
may
use
alon
combin
antih
antibodi
ohlin
et
al
nonetheless
like
explan
may
cell
function
essenti
cmv
control
vivo
neutral
antibodi
minim
activ
absenc
robust
cell
activ
boeckh
et
al
vzv
highli
transmiss
doublestrand
dna
poxviru
induc
febril
ill
chickenpox
character
children
fever
malais
prurit
vesicular
rash
cdc
vzv
also
reactiv
adulthood
seri
pain
vesicular
lesion
distribut
cutan
dermatom
infect
pregnant
women
first
second
trimest
may
induc
congenit
varicella
syndrom
result
signific
fetal
deform
vzv
infect
transmit
newborn
fatal
tan
koren
accordingli
vzv
immunoglobulin
vzig
indic
immunocompromis
patient
pregnant
women
neonat
risk
vzv
infect
cdc
tan
koren
nativ
human
antibodi
capabl
neutral
vzv
vitro
clone
foung
et
al
sugano
et
al
sugano
et
al
one
establish
use
human
hyperimmun
globulin
treatment
complic
vaccinia
viru
lane
et
al
henderson
et
al
vaccinia
viru
poxviru
adapt
use
human
vaccin
prevent
smallpox
although
gener
safe
immunocompet
person
dissemin
occasion
fatal
infect
occur
among
patient
underli
immunodefici
hiv
infect
eczema
atop
dermat
henderson
et
al
gener
vaccinia
syndrom
vv
prolifer
system
spread
bloodstream
redfield
et
al
progress
vv
infect
character
unrestrain
prolifer
viru
skin
eczema
vaccinatum
excess
prolifer
vv
skin
lesion
eczema
patient
condit
vig
indic
often
lead
complet
resolut
symptom
henderson
et
al
vig
also
use
immunocompet
individu
complic
infect
may
result
accident
infect
periorbit
region
lewi
et
al
creation
clone
neutral
antibodi
therapeut
vv
may
challeng
complex
life
cycl
vv
virion
exist
two
form
differ
abil
neutral
antibodi
intracellular
matur
virion
imv
extracellular
envelop
virion
eev
imv
suscept
neutral
eev
law
smith
smith
et
al
optim
protect
lethal
vv
murin
rhesu
macaqu
model
dna
vaccin
requir
combin
four
gene
direct
imv
eev
hooper
et
al
clone
nativ
murin
antibodi
specif
antigen
neutral
target
imv
abl
protect
mice
prophylact
therapeut
lethal
vv
challeng
ramirez
et
al
howev
compar
nativ
nonn
human
antibodi
describ
import
howev
determin
mani
clone
human
antibodi
requir
improv
symptom
vv
infect
immunocompromis
patient
rabi
viru
singlestrand
rna
genom
caus
acut
univers
fatal
enceph
efficaci
rig
postexposur
prophylaxi
rabi
review
elsewher
volum
see
chapter
nagarajan
et
al
briefli
human
rabi
immunoglobulin
hrig
use
combin
rabi
vaccin
known
suspect
rabi
exposur
administ
intraven
well
directli
suspect
exposur
site
see
chapter
nagarajan
et
al
volum
nativ
human
antibodi
clone
capabl
neutral
viru
vitro
vivo
reactiv
rabi
glycoprotein
dietzschold
et
al
gebauer
lindl
lafon
et
al
ueki
et
al
enssl
et
al
dorfman
et
al
nagarajan
et
al
volum
combin
two
human
antibodi
bind
noncrossresist
epitop
glycoprotein
undergon
preclin
vivo
test
one
antibodi
nativ
antibodi
clone
use
phage
display
method
champion
et
al
bakker
et
al
antibodi
combin
demonstr
efficaci
compar
hrig
interfer
potenc
simultan
administ
rabi
vaccin
de
kruif
et
al
rsv
singlestrand
negativestrand
viru
usual
caus
upper
respiratori
infect
welliv
patient
popul
rsv
infect
develop
bronchiol
inflamm
bronchiol
smallest
air
passag
lung
import
caus
mortal
young
children
elderli
vaccin
diseas
current
exist
shay
et
al
thompson
et
al
falsey
et
al
rsv
exist
two
main
subtyp
b
infect
one
subtyp
even
provid
lifelong
protect
reinfect
subtyp
welliv
prematur
infant
affect
bronchopulmonari
dysplasia
bpd
increas
risk
hospit
death
rsv
bronchiol
aujard
fauroux
preval
rsv
infect
popul
reduc
prophylact
treatment
rsvig
cdc
contrast
rsvig
show
efficaci
treatment
infant
alreadi
admit
hospit
diseas
rodriguez
et
al
rsv
may
also
caus
fatal
bronchiol
patient
undergo
allogen
stem
cell
transplant
offlabel
administr
rsvig
antivir
drug
ribavirin
may
reduc
mortal
devincenzo
et
al
ghosh
et
al
small
et
al
nativ
human
antibodi
neutral
rsv
clone
howev
human
murin
monoclon
antibodi
palivizumab
potent
substitut
rsv
first
demonstr
util
monoclon
antibodi
antivir
therapeut
young
see
chapter
h
wu
et
al
volum
palivizumab
bind
epitop
f
glycoprotein
viral
surfac
protein
major
target
neutral
antibodi
highli
conserv
type
b
virus
seri
highrisk
infant
prematur
andor
bpd
cours
monthli
prophylact
dose
palivizumab
reduc
overal
rate
seriou
infect
hospit
cdc
role
palivizumab
treatment
rsv
infect
elderli
allogen
hematopoiet
stem
cell
patient
yet
establish
potenc
ivig
hyperimmun
ig
monoclon
antibodi
palivizumab
demonstr
principl
human
antibodi
therapeut
like
effect
treatment
viral
diseas
vast
unmet
medic
need
exist
treatment
major
viral
diseas
occur
worldwid
develop
antivir
antibodi
therapeut
challeng
divers
viru
type
patient
popul
role
antibodi
play
neutral
specif
virus
abil
virus
mutat
antigen
domain
incomplet
understand
specif
featur
endow
antibodi
neutral
abil
counter
uncertainti
import
explor
divers
antibodi
repertoir
possibl
best
achiev
use
varieti
differ
complementari
method
human
antibodi
clone
efficaci
ivig
hyperimmun
ig
suggest
ideal
start
point
clone
human
antibodi
capabl
potent
neutral
viral
pathogen
may
b
cell
subject
develop
definit
antivir
bodi
respons
either
infect
vaccin
nativ
antibodi
librari
creat
affinitymatur
b
cell
would
expect
contain
individu
antibodi
possess
virusneutr
abil
would
suitabl
use
monoclon
oligoclon
antibodi
therapeut
success
nativ
human
antibodi
clone
method
obtain
nativ
human
antivir
antibodi
potenc
antibodi
establish
rational
explor
method
evid
effect
approach
depend
abil
creat
librari
come
close
possibl
comprehens
incorpor
entir
divers
human
antibodi
respons
viral
pathogen
preval
method
clone
human
antibodi
immun
human
repertoir
differ
bia
degre
sampl
antibodi
nativ
configur
eg
origin
heavi
chain
light
chain
pair
b
cell
immort
method
use
hybridoma
gener
ebv
infect
enabl
primari
human
b
cell
prolifer
vitro
theoret
take
unbias
sampl
repertoir
b
cell
express
antibodi
nativ
heavi
chain
light
chain
pair
addit
antibodi
describ
preced
section
method
use
clone
nativ
human
antibodi
specif
measl
hiv
sever
acut
respiratori
syndrom
sar
ebv
hepat
c
method
histor
challeng
poor
antibodi
yield
unstabl
antibodi
secret
nonetheless
focu
ongo
optim
effort
improv
abil
comprehens
access
nativ
human
antibodi
immunom
recombin
dna
method
offer
wellestablish
method
clone
human
antibodi
repertoir
method
heavi
chain
light
chain
variabl
domain
amplifi
b
cell
popul
use
rtpcr
fuse
express
singlechain
antigenbind
domain
scfv
surfac
filament
phage
barba
winter
et
al
screen
specif
antibodi
perform
pan
viru
bind
plate
solid
support
coat
antigen
bradburi
mark
relat
technolog
yeast
display
scfv
molecul
express
surfac
saccharomyc
cerevisia
boder
wittrup
yeast
display
allow
greater
diversif
express
antibodi
sequenc
mutagenesi
advantag
yeast
cell
express
human
antibodi
directli
screen
flow
cytometri
fluoresc
antigen
enabl
rapid
assess
bind
kinet
librari
scfv
antibodi
also
effici
express
surfac
escherichia
coli
daugherti
et
al
clear
recombin
dna
librari
obtain
immun
individu
differ
antibodi
obtain
nonimmun
individu
amersdorf
et
al
howev
process
creat
librari
introduc
bia
differ
step
process
may
hinder
abil
captur
entir
nativ
antibodi
repertoir
first
step
rtpcr
amplif
consensu
dna
primer
may
equal
amplifi
immunoglobulin
gene
sequenc
second
level
express
phage
e
coli
express
eukaryot
peptid
effici
human
variabl
domain
gene
sequenc
differ
significantli
one
anoth
length
amino
acid
composit
pavoni
et
al
combin
effect
could
potenti
reduc
preval
specif
antibodi
antibodi
librari
elimin
entir
evid
occur
come
dna
sequenc
analysi
complementaritydetermin
cdr
region
heavi
chain
variabl
domain
v
h
clone
phage
display
third
cdr
region
v
h
import
contributor
antigenbind
specif
antibodi
xu
davi
region
incorpor
phage
display
librari
tend
short
less
amino
acid
wherea
region
nativ
human
antibodi
vari
wide
length
mani
amino
acid
length
brezinschek
et
al
tian
et
al
shorter
region
correl
overal
greater
level
somat
hypermut
longer
region
may
better
capabl
viral
neutral
saphir
et
al
hangartn
et
al
tian
et
al
possibl
shorter
region
select
level
pcr
amplif
express
e
coli
two
studi
directli
examin
type
immun
librari
aris
phage
display
hybridoma
method
one
compar
studi
antibodi
clone
mice
immun
human
protein
use
phage
display
hybridoma
method
compar
ame
et
al
method
produc
structur
distinct
group
antibodi
antibodi
clone
hybridoma
method
abl
block
bind
cytokin
receptor
ohlin
borrebaeck
analyz
dataset
clone
antibodi
sequenc
specif
infecti
diseas
antigen
major
viral
clone
either
phage
display
hybridoma
method
ohlin
borrebaeck
note
substanti
differ
heavi
chain
light
chain
gene
famili
util
antibodi
deriv
two
differ
sourc
also
note
dramat
limit
divers
light
chain
gene
repertoir
observ
may
due
phenomenon
light
chain
promiscu
ie
abil
heavi
chain
product
associ
varieti
light
chain
kang
et
al
abil
phage
librari
recreat
nativ
heavi
chain
light
chain
combin
recent
assess
compar
phage
display
antibodi
librari
maintain
nativ
pair
one
made
cdna
meijer
et
al
random
librari
assort
heavi
chain
light
chain
sequenc
appar
lost
major
origin
heavi
chain
light
chain
pair
consist
principl
light
chain
promiscu
divers
random
librari
less
nonrandom
librari
due
overrepresent
vh
chain
capabl
associ
mani
differ
light
chain
sequenc
function
import
antibodi
repertoir
shift
random
librari
reveal
overal
lower
affin
antibodi
specif
tetanu
toxoid
tt
antibodi
clone
two
librari
taken
togeth
experi
illustr
concept
intrins
bias
phage
display
librari
may
prevent
import
nativ
antibodi
structur
incorpor
b
cell
immort
method
human
antibodi
clone
therefor
complementari
recombin
dna
method
thu
merit
studi
optim
start
point
nativ
human
antibodi
clone
method
sourc
virusimmun
b
cell
immun
individu
gener
antibodi
respons
effect
collabor
human
immun
system
cure
viral
infect
thu
presumpt
antibodi
requisit
biolog
function
exist
within
volunt
b
cell
donor
donor
subject
either
receiv
vaccin
specif
viru
surviv
infect
relev
viru
succumb
viral
infect
made
spleen
lymph
node
peripher
blood
mononuclear
cell
pbmc
avail
post
mortem
use
b
cell
varieti
genet
unrel
individu
increas
divers
nativ
antibodi
librari
screen
mani
approach
clone
human
antibodi
nativ
configur
part
involv
method
convert
primari
human
b
cell
form
viabl
vitro
ebv
immort
hybridoma
format
combin
protocol
ebv
immort
purifi
b
cell
infect
ebvcontain
supernat
marmoset
cell
line
brown
miller
method
effect
yet
compromis
low
level
antibodi
typic
express
ebvtransform
cell
lymphoblastoid
cell
lcl
stein
sigal
hybridoma
method
primari
human
b
cell
fuse
immort
fusion
partner
cell
line
adapt
vitro
cultur
capabl
produc
high
level
antibodi
immunoglobulin
gene
provid
primari
b
cell
primari
impedi
hybridoma
approach
low
hybrid
cell
yield
loss
antibodi
express
correl
loss
human
chromosom
hybrid
cell
combin
approach
taken
overcom
defect
immort
expand
antigenspecif
b
cell
popul
first
ebv
infect
fuse
immort
cell
murin
murinehuman
fusion
partner
cell
line
technolog
develop
area
attempt
address
problem
hybridoma
instabl
improv
fusion
partner
cell
line
origin
consid
human
cell
line
would
optim
fusion
partner
primari
human
b
cell
hybrid
cell
form
murin
cell
human
cell
known
segreg
human
chromosom
ephrussi
weiss
first
report
human
antibodi
clone
hybridoma
method
igm
antibodi
specif
measl
viru
croce
et
al
purpos
croce
et
al
use
human
myeloma
cell
line
fusion
partner
cell
pbmc
patient
subacut
scleros
panenceph
clinic
syndrom
result
measl
viru
infect
central
nervou
system
shortli
thereaft
appear
first
report
use
ebvimmort
b
cell
line
fusion
partner
clone
antibodi
specif
tt
chiorazzi
et
al
ebvimmort
human
b
cell
express
antibodi
cmv
fuse
human
myeloma
cell
line
give
hybrid
improv
antibodi
express
emanuel
et
al
enthusiasm
human
cell
line
temper
howev
due
problem
limit
number
immort
myeloma
b
cell
line
avail
kozbor
et
al
cell
line
low
fusion
rate
produc
slowgrow
hybridoma
mani
alreadi
express
human
antibodi
gene
chromosom
instabl
also
observ
consider
problem
olsson
et
al
experi
use
murin
myeloma
cell
line
fusion
partner
human
b
cell
demonstr
poor
effici
like
result
strong
tendenc
murinehuman
hybrid
cell
rapidli
segreg
human
chromosom
ephrussi
weiss
schlom
et
al
kozbor
et
al
koropatnick
et
al
compens
defect
intrins
human
murin
partner
cell
line
varieti
heteromyeloma
murin
human
cell
line
creat
gener
approach
taken
fuse
murin
myeloma
cell
line
human
cell
either
normal
pbmc
foung
et
al
ichimori
et
al
grunow
et
al
malign
cell
carrol
et
al
posner
et
al
faller
et
al
shirahata
et
al
examin
fusion
gener
result
hybrid
cell
chimer
murinehuman
genom
appear
improv
fusion
partner
creat
hybridoma
cell
stabli
secret
human
antibodi
instanc
heteromyeloma
contain
distinct
human
chromosom
contain
human
dna
detect
hybrid
analysi
probabl
form
murinehuman
chimer
chromosom
grunow
et
al
gustafsson
et
al
heteromyeloma
cell
line
possess
independ
metacentr
chromosom
consist
human
origin
foung
et
al
ichimori
et
al
carrol
et
al
faller
et
al
directli
compar
parent
murin
myeloma
cell
line
heterohybridoma
fusion
partner
cell
line
tend
improv
abil
give
rise
hybrid
cell
stabli
express
human
antibodi
foung
et
al
carrol
et
al
grunow
et
al
faller
et
al
mani
hybrid
cell
deriv
fusion
partner
cell
contain
substanti
number
human
chromosom
like
heteromyeloma
cell
line
better
abl
produc
hybrid
cell
reduc
tendenc
segreg
human
chromosom
foung
et
al
carrol
et
al
grunow
et
al
faller
et
al
use
heteromyeloma
fusion
partner
cell
line
wide
varieti
nativ
human
antibodi
clone
specif
import
viral
pathogen
includ
human
cell
lymphotrop
viru
cmv
hbv
hepat
c
viru
hcv
hiv
vzv
foung
et
al
carrol
et
al
grunow
et
al
bron
et
al
faller
et
al
gustafsson
et
al
hadlock
et
al
hadlock
et
al
along
improv
fusion
partner
cell
line
paramet
affect
rate
product
hybrid
cell
format
systemat
analyz
best
sourc
primari
human
b
cell
splenic
mononuclear
cell
tonsil
peripher
blood
mononuclear
cell
infant
olsson
et
al
grunow
et
al
jessup
et
al
karpa
et
al
time
harvest
b
cell
follow
vaccin
also
import
best
outcom
tt
antibodi
seen
cell
obtain
day
follow
vaccin
correspond
period
time
maximum
quantiti
ttspecif
memori
b
cell
circul
blood
butler
et
al
lanzavecchia
et
al
treatment
primari
b
cell
prolif
stimulu
prior
fusion
also
essenti
either
pokewe
mitogen
pwm
ebv
butler
et
al
larrick
et
al
olsson
et
al
cole
et
al
emanuel
et
al
pwm
superior
phytohemagglutinin
optim
use
day
olsson
et
al
arinbjarnarson
valdimarsson
costimul
mitogentr
cell
antigen
increas
yield
antigenspecif
antibodi
butler
et
al
sugano
et
al
cell
fusion
ratio
b
cell
immort
fusion
partner
cell
import
variabl
butler
et
al
perkin
et
al
two
group
investig
note
improv
fusion
effici
pbmc
expand
prior
cell
fusion
use
system
vitro
cell
cultur
method
use
antibodi
specif
interleukin
il
stimul
b
cell
prolifer
surviv
vitro
prior
cell
fusion
banchereau
rousset
darveau
et
al
thompson
et
al
benefit
expans
b
cell
system
ebvimmort
may
deriv
remov
cytotox
cell
fusion
may
threaten
viabil
nascent
heterohybridoma
cell
presum
express
varieti
murin
protein
antigen
context
human
mhc
may
recogn
foreign
human
cytotox
cell
popul
consist
hypothesi
borrebaeck
colleagu
demonstr
dramat
improv
yield
murinehuman
humanhuman
cell
fusion
treat
input
pbmc
l
leucin
methyl
ester
leuom
toxic
lysosomerich
cytolyt
cell
includ
natur
killer
nk
cell
cell
borrebaeck
et
al
borrebaeck
et
al
similar
potenti
effect
cytotox
unfus
cell
observ
kalantarov
et
al
murinehuman
fusion
partner
cell
line
carri
neo
drugresist
marker
inclus
cell
cultur
medium
postfus
substanti
reduc
variabl
yield
antibodysecret
hybrid
cell
principl
may
help
enrich
cell
popul
express
specif
antibodi
prior
cell
fusion
report
approxim
year
ago
casali
et
al
select
b
cell
express
antibodi
specif
tt
prior
ebv
immort
casali
et
al
recent
comparison
result
obtain
unselect
pbmc
fusion
perform
b
cell
increas
hybridoma
yield
schmidt
et
al
altern
tradit
chemic
method
induc
cell
fusion
polyethylen
glycol
peg
electrofus
offer
dramat
improv
rate
cell
fusion
pratt
et
al
foung
et
al
perkin
et
al
electrofus
cell
fuse
align
hypoosmolar
buffer
solut
use
altern
current
fusion
induc
one
burst
direct
current
electrofus
use
varieti
fusion
partner
cell
line
includ
lymphoblastoid
heteromyeloma
murin
myeloma
cell
line
pratt
et
al
foung
et
al
yoshinari
et
al
three
studi
directli
compar
effici
electrofus
polyethylen
glycol
peg
fusion
estim
appar
superior
electrofus
maxim
calcul
fusion
rate
approxim
cell
per
input
human
b
cell
perkin
et
al
krenn
et
al
panova
gustafsson
improv
viabil
hybrid
cell
follow
fusion
delay
h
prior
initi
hat
select
hypoxanthin
aminopterin
thymidin
use
cell
feeder
layer
support
hybridoma
growth
also
found
help
cote
et
al
perkin
et
al
hoffmann
et
al
shirahata
et
al
improv
continu
made
fusion
partner
cell
line
karpa
cell
line
neartetraploid
human
myeloma
cell
line
specif
select
improv
growth
rate
vitro
resist
peg
requir
cell
fusion
toxic
origin
myeloma
cell
line
karpa
effect
fuse
tonsillar
b
cell
lymphoblastoid
cell
notabl
creation
hybridoma
secret
antibodyml
cultur
medium
analysi
antibodi
clone
thymocyt
fuse
karpa
cell
line
reveal
spectrum
antibodi
repres
differ
stage
b
cell
differenti
process
vaisbourd
et
al
novel
heterohybridoma
cell
line
actual
progeni
two
cell
fusion
first
murin
myeloma
cell
line
human
myeloma
cell
line
second
one
result
heterohybridoma
primari
human
lymphocyt
obtain
lymph
node
addit
modifi
express
neo
resist
gene
enabl
neg
select
cytotox
cell
follow
cell
fusion
cell
line
notabl
fusion
clone
effici
karyotyp
demonstr
intact
human
chromosom
chromosom
partial
human
chromosom
chimer
murinehuman
chromosom
cell
line
also
use
clone
antibodi
specif
breast
cancer
antigen
kirman
et
al
import
altern
hybridoma
method
recent
improv
ebvimmort
method
human
primari
igg
b
cell
stimul
cpg
oligonucleotid
prior
ebv
exposur
hartmann
krieg
traggiai
et
al
polyclon
b
cell
prolifer
increas
rate
ebv
immort
addit
effici
clone
transform
cell
improv
includ
cpg
oligonucleotid
cultur
medium
use
irradi
mononuclear
cell
layer
other
note
lymphoblastoid
cell
tend
unstabl
igg
express
immort
cell
found
produc
antibodyml
supernat
stabl
enough
enabl
vitro
vivo
function
experi
stein
sigal
traggiai
et
al
method
enabl
clone
panel
igg
antibodi
specif
either
nucleoprotein
spike
protein
sar
viru
abl
significantli
reduc
prolifer
viru
murin
diseas
model
traggiai
et
al
improv
also
made
phage
display
method
may
mitig
factor
hinder
incorpor
nativ
human
antibodi
gene
typic
phage
display
librari
describ
meijer
et
al
employ
novel
approach
incel
singlecel
pcr
consensu
oligonucleotid
produc
individu
correctli
pair
scfv
cell
meijer
et
al
scfv
use
creat
phage
display
librari
screen
analysi
pair
sequenc
produc
method
demonstr
consist
pair
heavi
light
chain
indic
preserv
nativ
pair
antibodi
conform
littl
understood
caus
intrins
instabl
hybridoma
form
primari
human
b
cell
segreg
human
chromosom
murinehuman
hybrid
cell
ephrussi
weiss
cieplinski
et
al
harri
et
al
begin
address
question
empir
other
consid
empir
modif
fusion
partner
cell
ectop
gene
express
may
provid
insight
natur
hybridoma
cell
potenti
improv
util
first
experi
along
line
base
observ
addit
cultur
medium
murinemurin
cell
fusion
could
increas
proport
hybrid
cell
express
murin
antibodi
bazin
lemieux
essenti
myeloma
cell
growth
possess
prolif
antiapoptot
function
addit
abil
directli
stimul
antibodi
gene
express
hirano
addit
hybridoma
cultur
medium
improv
clone
effici
antibodi
secret
establish
hybridoma
zhu
et
al
cell
ectop
express
high
level
found
give
improv
yield
hybridoma
secret
antigenspecif
nonspecif
antibodi
compar
untransfect
parent
cell
harri
et
al
similar
experi
perform
goal
improv
stabil
murinehuman
cell
fusion
zhu
et
al
share
mani
function
ectop
express
murin
fusion
partner
cell
line
express
improv
yield
hybridoma
follow
select
effect
note
mitogenstimul
ebvtransform
b
cell
express
also
increas
quantiti
antibodi
produc
hybrid
deriv
stabl
lcl
howev
data
given
longterm
stabil
hybridoma
like
still
prone
segreg
human
chromosom
associ
loss
antibodi
express
perform
similar
experi
compar
abil
fusion
partner
cell
line
form
stabl
hybrid
human
splenic
b
cell
express
abl
overcom
instabl
result
segreg
human
chromosom
dessain
et
al
k
rybinski
adekar
b
barnoski
dessain
unpublish
data
origin
consid
ectop
express
human
telomeras
htert
may
improv
fusion
human
b
cell
human
immort
fusion
partner
cell
line
humanhuman
hybridoma
affect
poor
prolifer
rate
chromosom
loss
phenotyp
associ
cell
cultur
system
telomer
dysfunct
olsson
et
al
counter
et
al
bailey
murnan
prior
discoveri
htert
experi
shown
mortal
human
cell
impos
domin
senesc
program
fuse
immort
human
cell
pereirasmith
et
al
later
microcel
fusion
experi
reveal
introduct
intact
copi
human
chromosom
immort
htertexpress
cell
line
repress
htert
activ
caus
cellular
senesc
oshimura
barrett
togeth
result
suggest
humanhuman
hybrid
cell
form
immort
fusion
partner
cell
line
primari
human
b
cell
suffer
htert
defici
unfortun
initi
experi
human
fusion
partner
cell
line
suggest
defici
multifactori
could
overcom
sole
ectop
htert
express
dessain
r
goldsbi
r
weinberg
data
shown
murin
fusion
partner
cell
line
much
better
form
hybrid
human
fusion
partner
perform
similar
experi
cell
line
shulman
et
al
cell
line
poor
fusion
partner
primari
human
b
cell
serv
use
start
point
assess
affect
ectop
gene
express
jessup
et
al
murinehuman
hybrid
cell
htert
could
potenti
contribut
hybrid
cell
stabil
speciesspecif
stabil
human
telomer
addit
htert
shown
mani
function
may
benefici
hybrid
cell
includ
incomplet
character
tumorpromot
function
may
relat
antiapoptot
growth
factorstimulatori
activ
holt
et
al
stewart
et
al
kanzaki
et
al
smith
et
al
found
heterohybridoma
cell
form
cell
line
primari
human
b
cell
express
murin
tert
mtert
htert
introduc
htert
cell
observ
modest
increas
number
cell
express
htert
without
use
longterm
mainten
human
antibodi
express
dessain
r
goldsbi
r
weinberg
data
shown
contrast
ectop
express
combin
htert
readili
enabl
creation
stabl
hybrid
cell
secret
human
antibodi
notabl
hybridoma
result
fusion
contain
consider
number
intact
human
chromosom
even
month
continu
cultur
vitro
dessain
et
al
exampl
shown
fig
human
chromosom
karyotyp
humanmurin
hybridoma
cell
secret
nonneutr
igm
antibodi
specif
vaccinia
viru
antigen
virtual
full
diploid
human
genom
present
addit
murin
chromosom
week
follow
creation
hybrid
cell
appar
cooper
benefit
htert
gene
may
result
mechan
wherebi
express
may
promot
mainten
human
chromosom
nascent
hybridoma
cell
hybrid
cell
creat
cell
human
primari
b
cell
prolifer
cultur
human
chromosom
repress
express
hybrid
cell
ebel
et
al
therefor
prolifer
hybrid
cell
vivo
may
possibl
chromosom
lost
indirectli
select
cell
rapidli
segreg
human
chromosom
specif
mechan
wherebi
htert
collabor
chromosom
mainten
investig
follow
establish
cell
fusion
drug
select
hybridoma
need
screen
specif
antibodi
express
optim
approach
thoroughli
explor
nativ
antibodi
immunom
hybridoma
would
fig
human
chromosom
humanmurin
heterohybridoma
shown
gband
human
chromosom
hybridoma
secret
human
antibodi
murin
chromosom
shown
stabl
antibodi
express
result
abil
hybrid
cell
maintain
intact
human
chromosom
assay
individu
bind
specif
particular
antibodi
practic
consider
hybridoma
gener
assay
pool
dozen
clone
advanc
screen
technolog
may
significantli
increas
yield
specif
antivir
antibodi
could
obtain
new
antibodi
screen
method
differ
achiev
core
object
associ
individu
cell
antibodi
produc
select
lymphocyt
antibodi
method
slam
primari
b
cell
cultur
presenc
complement
sheep
red
blood
cell
srbc
conjug
antigen
interest
babcook
et
al
b
cell
express
antibodi
specif
srbcconjug
antigen
identifi
secret
antibodi
caus
local
hemolyt
reaction
although
origin
conceiv
method
would
use
primari
b
cell
immunoglobulin
gene
would
directli
clone
rtpcr
method
may
use
screen
hybridoma
ebvtransform
cell
three
method
combin
isol
individu
hybridoma
cell
fluoresc
assay
antigen
bind
first
distribut
individu
hybridoma
tini
well
nl
volum
creat
glass
slide
use
microengrav
techniqu
love
et
al
secret
antibodi
captur
analysi
sandwich
array
hybridoma
supernat
captur
slide
coat
secondari
antibodi
antigen
bound
complex
detect
fluoresc
label
antigen
secondari
antibodi
respect
multipl
captur
slide
use
singl
hybridoma
microarray
enabl
cell
screen
varieti
antigenbind
specif
altern
method
immobil
hybridoma
filter
secret
antibodi
diffus
bind
plate
coat
secondari
antibodi
wwwtrellisbiocom
potera
plate
probe
panel
fluoresc
probe
use
combinatori
fashion
allow
simultan
screen
mani
differ
antigen
computer
microscopi
use
analyz
bind
reaction
hybridoma
also
envelop
agaros
matrix
captur
antibodi
secret
hybridoma
purpos
secondari
antibodi
attach
agaros
biotinavidin
bridg
gray
et
al
secret
antibodi
thu
stabli
associ
cell
produc
porou
agaros
matrix
enabl
hybridoma
screen
bind
fluoresc
label
antigen
matrix
also
offer
structur
stabil
hybridoma
analyz
sort
fac
one
laboratori
jb
begun
experi
fmat
cellular
detect
system
system
use
antigenco
bead
mix
hybridoma
supernat
fluoresc
label
secondari
antibodi
format
secondari
antibodi
detect
specif
antibodi
bound
bead
therebi
concentr
fluoresc
punctat
signal
detect
mechan
plate
reader
advantag
method
enabl
highthroughput
screen
hybridoma
supernat
provid
mean
isol
singl
cell
prior
screen
final
marriag
cell
screen
technolog
autom
cell
manipul
clonepix
wwwgenetixcom
acceler
process
mine
nativ
human
antibodi
immunom
obtain
antibodi
use
treatment
viral
diseas
press
demand
antibodi
use
antivir
therapeut
mandat
broadbas
effort
util
avail
antibodi
clone
technolog
parallel
clone
method
directli
immort
b
cell
hybridoma
creation
ebv
infect
complement
recombin
dna
transgen
mous
method
antibodi
clone
unbias
access
antibodi
repertoir
nativ
configur
addit
method
simplifi
explor
antibodi
repertoir
genet
divers
individu
past
year
success
technic
advanc
improv
method
clone
nativ
human
antibodi
may
abl
contribut
meaning
ongo
effort
phage
display
transgen
mous
method
simplic
method
facilit
applic
laboratori
divers
research
interest
well
provid
rational
creat
core
facil
provid
highthroughput
screen
servic
academ
research
